Thiogenesis to Present Clinical Updates in MELAS and Leigh Syndrome Spectrum at UMDF Bench-to-Bedside Webinar

Rhea-AI Summary

Thiogenesis (OTCQX: TTIPF) announced that CEO Patrice Rioux, MD, Ph.D. will present clinical updates at the United Mitochondrial Disease Foundation Bench-to-Bedside webinar on January 5, 2026. The presentation will cover the lead candidate TTI-0102, including results from a recently completed EU Phase 2 MELAS trial and plans for a Phase 2a Leigh syndrome spectrum (LSS) trial expected to begin in the first quarter of 2026 in the United States.

The company said the U.S. Phase 2a LSS trial is planned in collaboration with a leading pediatric hospital and that TTI-0102 is being developed to address mitochondrial oxidative stress, a key pathological feature across multiple inherited mitochondrial disorders for which no approved therapies currently exist.

Dr. Rioux Will Present on Phase 2 MELAS Program & Upcoming Phase 2a Leigh Syndrome Trial

San Diego, California--(Newsfile Corp. - January 5, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing next-generation sulfur-based prodrugs for rare mitochondrial and metabolic diseases, today announced that its Chief Executive Officer, Patrice Rioux, MD, Ph.D., will participate as a panelist in the United Mitochondrial Disease Foundation's ("UMDF") 2026 Bench-to-Bedside webinar on January 5, 2026.

During the session, Dr. Rioux will provide clinical updates on Thiogenesis' lead product candidate, TTI-0102, including an update on the Company's Phase 2 clinical program in Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes ("MELAS"), as well as plans for its upcoming Phase 2a clinical trial in Leigh syndrome spectrum ("LSS") in the United States.

Thiogenesis' two lead clinical programs include:

• An EU Phase 2 clinical trial in MELAS that was conducted at leading academic medical centers in Europe and recently completed

• A planned Phase 2a U.S. clinical trial in Leigh syndrome spectrum, expected to initiate in the first quarter of 2026 in collaboration with a leading pediatric hospital

"I am pleased to participate in UMDF's Bench-to-Bedside webinar and to provide an update on Thiogenesis' clinical programs in MELAS and Leigh syndrome spectrum," said Patrice Rioux, MD, Ph.D., Chief Executive Officer and Co-Founder of Thiogenesis. "TTI-0102 is being developed to address mitochondrial oxidative stress, a central pathological feature of multiple inherited mitochondrial disorders for which there are currently no approved therapies."

About UMDF

The United Mitochondrial Disease Foundation's mission is to promote research and education for the diagnosis, treatment, and cure of mitochondrial disorders and to provide support to affected individuals and families. For more than 25 years, UMDF has supported a global network of clinicians, researchers, and patient advocates dedicated to advancing mitochondrial disease research and improving patient outcomes.

About MELAS

Mitochondrial encephalopathy with lactic acidosis and stroke-like episodes ("MELAS") is an inherited mitochondrial disorder, most often caused by a mutation of m.3243A>G in the MT-TL1 gene in mitochondrial DNA. Initial symptoms usually include seizures, vomiting, headaches, muscle weakness, loss of appetite and fatigue. Oxidative stress, including deficiencies in glutathione and taurine, play an important role in mitochondria dysfunction and are potential pathological mechanisms of mitochondrial disorders, making for viable targets for the treatment of MELAS and other mitochondrial diseases. Although it is one of the more prevalent inherited mitochondrial diseases, MELAS is still considered an orphan disease. There are estimated to be approximately 4.1/100,000 of the population with MELAS worldwide.

About Leigh Syndrome Spectrum

Leigh syndrome spectrum is a rare, inherited genetic disease that affects the power plant of the cell, the mitochondria. It is usually diagnosed in infancy and occurs in an estimated 1/40,000 live births. Symptoms include weak sucking/breastfeeding, loss of motor and communication skills, poor muscle development, respiratory issues, weakness/fatigue and seizures. There are currently no approved drugs for Leigh syndrome spectrum.

About TTI-0102

TTI-0102 is Thiogenesis' lead product candidate and a next-generation cysteamine-based prodrug designed to address limitations associated with first-generation thiol therapies, including short half-life, gastrointestinal side effects, and dosing constraints. As a prodrug, TTI-0102 is metabolized following ingestion, enabling controlled release of cysteamine with the potential for improved tolerability and once-daily dosing. TTI-0102 is being evaluated across multiple indications associated with mitochondrial dysfunction and oxidative stress.

About Thiogenesis Therapeutics

Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) is a clinical-stage biopharmaceutical company with operations based in San Diego, California. The Company is publicly traded on the TSX Venture Exchange and in the U.S. on the OTCQX. Thiogenesis is developing sulfur-containing prodrugs that act as precursors to previously approved thiol-active compounds, with the potential to treat serious pediatric diseases with unmet medical needs. Thiogenesis' lead product candidate, TTI-0102 has an active Phase 2 clinical trial in Mitochondrial Encephalopathy Lactic Acidosis and Stroke ("MELAS"), an IND-cleared Phase 2a clinical trial planned in Leigh syndrome spectrum, a Phase 2 clinical trial planned in pediatric Metabolic Dysfunction-Associated Steatohepatitis ("MASH") and a Phase 3 clinical trial planned in nephropathic cystinosis.

For further information, please contact:
Brook Riggins, Director, and CFO
Email: info@thiogenesis.com
Tel.: (888) 223-9165

Forward-Looking Statements

This news release contains certain forward-looking statements and forward-looking information (collectively referred to herein as "forward- looking statements") within the meaning of Canadian securities laws including, without limitation, statements with respect to the future investments by the Company. All statements other than statements of historical fact are forward-looking statements. Undue reliance should not be placed on forward-looking statements, which are inherently uncertain, are based on estimates and assumptions, and are subject to known and unknown risks and uncertainties (both general and specific) that contribute to the possibility that the future events or circumstances contemplated by the forward-looking statements will not occur. Although the Company believes that the expectations reflected in the forward-looking statements contained in this press release, and the assumptions on which such forward-looking statements are made, are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking statements included in this document, as there can be no assurance that the plans, intentions, or expectations upon which the forward-looking statements are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause the Company's actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. The forward-looking statements contained in this news release are made as of the date hereof and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, except as required by applicable law. The forward-looking statements contained herein are expressly qualified by this cautionary statement.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) nor the OTC Markets Group Inc. (OTCQX: OTCM) accepts responsibility for the adequacy or accuracy of this news release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/279392

FAQ

When will Thiogenesis (TTIPF) present clinical updates at the UMDF webinar?

Thiogenesis will present on January 5, 2026 at the UMDF Bench-to-Bedside webinar.

What clinical programs will Thiogenesis (TTIPF) update at the January 5, 2026 webinar?

The update will cover TTI-0102, including a completed EU Phase 2 MELAS trial and plans for a Phase 2a LSS trial in the U.S.

When is Thiogenesis (TTIPF) planning to start the Phase 2a Leigh syndrome spectrum trial in the U.S.?

The company expects the Phase 2a LSS trial to initiate in the first quarter of 2026.

What is TTI-0102 designed to target for patients in Thiogenesis trials (TTIPF)?

TTI-0102 is being developed to address mitochondrial oxidative stress, a central pathological feature of several inherited mitochondrial disorders.

Where was the Phase 2 MELAS trial for Thiogenesis (TTIPF) conducted?

The Phase 2 MELAS trial was conducted at leading academic medical centers in Europe and has recently completed.

Who from Thiogenesis (TTIPF) will present at the UMDF Bench-to-Bedside webinar?

Chief Executive Officer Patrice Rioux, MD, Ph.D. will participate as a panelist and provide the clinical updates.